Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1515/cclm-2024-0986 | DOI Listing |
Med Biol Eng Comput
January 2025
Anhui BioX-Vision Biological Technology Co., Ltd, Hefei, 230031, Anhui, China.
The identification and categorization of circulating tumor cells (CTCs) in peripheral blood are imperative for advancing cancer diagnostics and prognostics. The intricacy of various CTCs subtypes, coupled with the difficulty in developing exhaustive datasets, has impeded progress in this specialized domain. To date, no methods have been dedicated exclusively to overcoming the classification challenges of CTCs.
View Article and Find Full Text PDFMol Oncol
January 2025
Division of Oncology, Department of Medicine I, Medical University of Vienna, Austria.
Late-line treatment in metastatic colorectal cancer (mCRC) can improve prognosis. However, not every patient has a benefit and may experience severe side effects. Thus, predictive/prognostic biomarkers are urgently needed.
View Article and Find Full Text PDFImmunol Invest
January 2025
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, China.
Tissue-resident memory T (TRM) cells possess unique abilities to migrate, establish themselves in tissues, and monitor peripheral tissues without circulating. They are crucial in providing long-lasting and local immune protection against surface infections. TRMs demonstrate distinct phenotypic and functional characteristics compared to central memory T (Tcm) cells and effector memory T (Tem) cells.
View Article and Find Full Text PDFAdv Healthc Mater
January 2025
Nitte (Deemed to be University), Department of Bio & Nano Technology, Nitte University Centre for Science Education and Research, Mangalore, Karnataka, 575018, India.
Therapeutic strategy for efficiently targeting cancer cells needs an in-depth understanding of the cellular and molecular interplay in the tumor microenvironment (TME). TME comprises heterogeneous cells clustered together to translate tumor initiation, migration, and proliferation. The TME mainly comprises proliferating tumor cells, stromal cells, blood vessels, lymphatic vessels, cancer-associated fibroblasts (CAFs), extracellular matrix (ECM), and cancer stem cells (CSC).
View Article and Find Full Text PDFMol Oncol
January 2025
Urologic Oncology Research Group, Cancer Research Program, Research Institute of the McGill University Health Center, Montreal, Canada.
Patient stratification remains a challenge for optimal treatment of prostate cancer (PCa). This clinical heterogeneity implies intra-tumoural heterogeneity, with different prostate epithelial cell subtypes not all targeted by current treatments. We reported that such cell subtypes are traceable in liquid biopsies through representative transcripts.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!